|
Age (at cohort entry)
|
1.19
|
1.10, 1.28
|
|
Age (at cohort entry) squared
|
1.00
|
1.00, 1.00
|
|
Female sex
|
0.80
|
0.66, 0.96
|
|
Recipient of social assistance at cohort entry
|
0.89
|
0.59, 1.35
|
|
Baseline urban residence
|
1.03
|
0.82, 1.28
|
|
Baseline regional employment ratea
|
1.00
|
0.98, 1.01
|
|
Baseline regional family incomea
|
1.00
|
0.99, 1.01
|
|
Baseline regional percent university graduatesa
|
1.00
|
0.99, 1.01
|
|
Extra-articular RA manifestations (time-dependent)
|
1.08
|
0.91, 1.28
|
|
Rheumatology visits at baseline (log-transformed)
|
1.24
|
1.11, 1.38
|
|
Rheumatology visits in follow up, time dependent (log-transformed)
|
0.98
|
0.84, 1.15
|
|
High health care use at baseline
|
1.11
|
0.91, 1.35
|
|
Prior joint replacement
|
2.55
|
1.90, 3.43
|
|
Baseline comorbidities
| | |
|
Myocardial infarction
|
0.86
|
0.48, 1.56
|
|
Diabetes
|
0.99
|
0.76, 1.28
|
|
Osteoporosis
|
0.79
|
0.63, 0.99
|
|
Cerebrovascular disease
|
1.27
|
0.40, 4.02
|
|
Acute renal failure
|
1.16
|
0.68, 1.97
|
|
Chronic renal failure
|
1.60
|
0.90, 2.84
|
|
Coronary artery disease
|
1.01
|
0.81, 1.27
|
|
COPD-asthma
|
0.96
|
0.77, 1.18
|
|
Any type of cancer
|
1.01
|
0.72, 1.41
|
|
Osteoarthritis
|
2.15
|
1.81, 2.55
|
|
Charlson Comorbidity
|
0.92
|
0.85, 1.00
|
|
Drug use prior to cohort entry
| | |
|
Anti-TNF
|
1.00
|
0.35, 2.85
|
|
MTX
|
1.27
|
0.94, 1.70
|
|
Other DMARDs
|
1.13
|
0.88, 1.45
|
|
Systemic corticosteroids
|
1.15
|
0.97, 1.38
|
|
COXIBs
|
0.97
|
0.82, 1.15
|
|
NSAIDs
|
0.87
|
0.73, 1.03
|
|
Time-dependent cumulative drugs in follow up (years)
| | |
|
Anti-TNF
|
1.13
|
0.99, 1.29
|
|
Other biologic drugs
|
1.37
|
0.61, 3.08
|
|
Systemic corticosteroids
|
1.01
|
0.94, 1.08
|
|
COXIBs
|
1.20
|
1.11, 1.30
|
|
NSAIDs
|
1.31
|
1.20, 1.43
|
|
Cumulative MTX in first year (months)
|
0.94
|
0.92, 0.96
|
|
Cumulative other DMARDs in first year months)
|
0.97
|
0.95, 0.99
|
